Pharma's Almanac TV
PA TV
Follow the Journey
Companies We've Met
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Current Issue
Archive
Reports
Biologics Pricing Report
Oral Solid Dose Market Report
Community
Company A to Z
Content Filter
More+
Staffing
Media Kit
By The Numbers
Innovation
447 Articles Available
1
19
Can't find what you're looking for? Try our
advanced search
.
Innovative Approach to Process Development
PAO-02-21-CL-02
Industry Leader
Shaping the Future of Biopharma Through Next-Generation Contract Drug Manufacturing
PAP-Q4-20-CL-023
Gene Sequencing
Expanding Laboratory Access to Gene Sequencing
PAP-Q4-20-CL-022
The Future of Healthcare
How Does Pii Envision the Future of the Pharma/Biopharma Industry?
PAP-Q4-20-RT2-012
Gene Therapy
Anticipating the Next Decade of Gene Therapy
PAO-11-20-CL-02
Recombinant Proteins
Innovation and Flexibility Drive Success During the COVID-19 Pandemic
PAP-Q3-20-CL-019
Organ-on-a-Chip
Organ-on-a-Chip Technology Aims to Disrupt Traditional Drug Testing Models
PAP-Q3-20-CL-014
Bioanalysis
How Bioanalysis Supports the Development of New Cell and Gene Therapies
PAP-Q3-20-CL-012
The Future of Healthcare
How Is Polpharma Biologics Evolving its Business Model to Meet the Future of Healthcare?
PAP-Q3-20-RT2-007
The Future of Healthcare
How Is Pii Evolving its Business Model to Meet the Future of Healthcare?
PAP-Q3-20-RT2-005
Plasma Proteins
Therapeutic Potential of Novel Plasma Protein Production Technology
PAP-Q3-20-CL-029
Biomaterials
Innovative Biomaterials Facilitate Novel Medical Devices
PAP-Q2-20-CL-026
The Future of Healthcare
How is Olon Innovating through the Pandemic and Beyond to Define the Future of Healthcare?
PAP-Q2-20-RT2-003
The Future of Healthcare
How is Polpharma Biologics Innovating through the Integration of Advanced Cell Line Development Capabilities to Help Shape the Future of Healthcare?
PAP-Q2-20-RT2-004
The Future of Healthcare
How is Pii Innovating through the Pandemic and Beyond to Define the Future of Healthcare?
PAP-Q2-20-RT2-009
Roundtable
Q: What two or three drug molecules do you identify as having had the greatest impact on society? What about on the pharmaceutical industry?
PAP-Q2-20-RT-002
Innovation
HKBU Scientists Eliminate Drug Side Effects by Manipulating Molecular Chirality
PR-M05-20-NI-029
Artificial Intelligence
Facilitating Drug Re-Innovation with Artificial Intelligence
PAP-Q1-20-CL-020
Spray Drying
Providing Solutions at Fair Value: A Spray Drying Case Study
PAO-03-20-CL-002
3D Printing
Merck KGaA, Darmstadt, Germany and AMCM / EOS Cooperate in 3D Printing of Tablets
PR-M02-20-NI-042
3D Bioprinting
Missouri S&T Researchers Create Organ Tissue with Bioactive Glass, Stem Cells and 3D Printer
PR-M02-20-NI-028
Innovation
AstraZeneca-Singapore Establish Strategic Partnerships to Improve Health through Innovation
PR-M02-20-NI-015
Series B Funding
TISSIUM Closes €39M Series B Funding Round
PR-M11-19-NI-026
Cannabinoids
Leveraging Biosynthetic Expertise to Access a Wide Portfolio of Cannabinoids
PAP-Q3-19-CL-031
1
19
»
